NCT04666038 2026-04-24BRUIN CLL-321Eli Lilly and CompanyPhase 3 Active not recruiting238 enrolled 17 charts 1 FDA
NCT03740529 2026-01-27A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHLEli Lilly and CompanyPhase 1/2 Completed803 enrolled 2 FDA